Emerging platform Inso Biosciences offers a novel solid-phase DNA capture platform using microfluidics from Cornell, presenting a disruptive front-end sample preparation alternative that can enable partnerships with established sequencing and workflow providers seeking affordable automation and higher throughput.

Automation potential The technology is designed for automated, integrated on-chip extraction and enzymatic processing with minimal setup, creating sales opportunities with biotech labs and contract research organizations looking to streamline sample-to-answer workflows and scale genomic applications.

Early-stage funding With pre-seed and state-grant funding recently secured, there is momentum and validated backing for growth; potential customers or partners can align with grants-oriented collaboration opportunities or co-development initiatives.

Strengthen endpoints The platform emphasizes preservation of long DNA fragments and multiomic capabilities, suggesting cross-sell opportunities to customers pursuing long-read sequencing, multi-omic assays, or integrated genomic diagnostics.

Strategic fits Target high-impact users and adjacent markets in academia and biotech services, especially those leveraging beaded or column-based sample prep today; propose pilots or joint development to accelerate adoption within organizations similar to Bio-Rad, Illumina, or 10x Genomics ecosystems.